Loading stock data…
$4.72-0.26 (-5.22%)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Atea Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.72 with a market capitalization of $422M. Wall Street consensus targets $9.42 (3 analysts), implying a +99.5% move over the next 12 months. The stock is currently 27% below its 52-week high of $6.45, remaining 3.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$35.10M↑ | -$48.01M↑ | -$54.93M↓ | -$45.57M↓ | -$41.34M |
| Net Income | -$32.93M↑ | -$45.44M↓ | -$44.87M↓ | -$42.05M↓ | -$37.16M |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucl...